Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Laron syndrome
Introduction
For patient information click here
Synonyms and keywords: Growth Harmone Receptor Deficiency; Growth hormone insensitivity syndrome; pituitary dwarfism II; Laron syndrome due to postreceptor defect; growth hormone insensitivity due to postreceptor defect; Laron-type dwarfism
Overview
Overview
Laron syndrome is a autosomal recessive disorder characterized by an insensitivity to growth hormone (GH), caused by a variant of the growth hormone receptor. It causes short stature.
References
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Historical Perspective
Overview
Historical perspective
It is named after Zvi Laron, the Israeli researcher who, with A. Pertzelan and S. Mannheimer, first reported the condition in 1966[1][2], based upon observations which began in 1958.[3]
Resistance to GH was first reported by Laron in 1966. Since then, severe resistance to GH, characterized by grossly impaired growth despite normal levels of GH in serum, has been termed Laron syndrome.
Homo floresiensis
Recent publications have proposed that Homo floresiensis represented a population with widespread Laron syndrome.[4][5]
References
- ↑ Template:WhoNamedIt
- ↑ Laron Z, Pertzelan A, Mannheimer S (1966). “Genetic pituitary dwarfism with high serum concentation of growth hormone–a new inborn error of metabolism?”. Isr. J. Med. Sci. 2 (2): 152–5. PMID 5916640.
- ↑ Laron Z (2004). “Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003”. J. Clin. Endocrinol. Metab. 89 (3): 1031–44. PMID 15001582.
- ↑ Hershkovitz I, Kornreich L, Laron Z (2007). “Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron syndrome)”. Am. J. Phys. Anthropol. 134 (2): 198–208. doi:10.1002/ajpa.20655. PMID 17596857.
- ↑ Culotta E (2007). “Paleoanthropology. The fellowship of the hobbit”. Science. 317 (5839): 740–2. doi:10.1126/science.317.5839.740. PMID 17690271.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Classification
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
References
Pathophysiology
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
Pathophysiology
Molecular genetic investigations have shown that this disorder is mainly associated with mutations in the gene for the GH receptor. These can result in defective hormone binding to the ectodomain or reduced efficiency of dimerization of the receptor after hormone occupancy. There are exceptionally low levels of insulin growth factor (IGF-1) and its principal carrier protein, insulin-like growth factor binding protein 3. Laron syndrome is a autosomal recessive disorder.
References
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Causes
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
References
Differentiating Laron Syndrome from other Diseases
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
References
Epidemiology and Demographics
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
Epidemiology and Demographics
The majority of reported cases have been of Mediterranean or semitic origin, with numerous patients in Israel, Ecuador, Turkey and in the Bahamas.
References
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Risk Factors
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
References
Natural History, Complications and Prognosis
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
References
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S